JP2020121985A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020121985A5 JP2020121985A5 JP2020068158A JP2020068158A JP2020121985A5 JP 2020121985 A5 JP2020121985 A5 JP 2020121985A5 JP 2020068158 A JP2020068158 A JP 2020068158A JP 2020068158 A JP2020068158 A JP 2020068158A JP 2020121985 A5 JP2020121985 A5 JP 2020121985A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- weeks
- manufactured
- period
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims description 44
- 150000001875 compounds Chemical class 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 17
- 229930105110 Cyclosporin A Natural products 0.000 claims description 16
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 16
- 108010036949 Cyclosporine Proteins 0.000 claims description 16
- 229960001265 ciclosporin Drugs 0.000 claims description 15
- 230000003287 optical effect Effects 0.000 claims description 15
- 239000012453 solvate Substances 0.000 claims description 15
- 150000002148 esters Chemical class 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 11
- 150000004677 hydrates Chemical class 0.000 claims description 9
- 230000004968 inflammatory condition Effects 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 230000002458 infectious effect Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 6
- 206010010741 Conjunctivitis Diseases 0.000 claims description 4
- 206010039705 Scleritis Diseases 0.000 claims description 4
- 206010046851 Uveitis Diseases 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims 18
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 description 6
- 102100032818 Integrin alpha-4 Human genes 0.000 description 5
- 108010041012 Integrin alpha4 Proteins 0.000 description 5
- 229960004833 dexamethasone phosphate Drugs 0.000 description 4
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- -1 limexolone Chemical compound 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 102100022339 Integrin alpha-L Human genes 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 229960003655 bromfenac Drugs 0.000 description 2
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229960001048 fluorometholone Drugs 0.000 description 2
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 2
- 229960001629 fluorometholone acetate Drugs 0.000 description 2
- YRFXGQHBPBMFHW-SBTZIJSASA-N fluorometholone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 YRFXGQHBPBMFHW-SBTZIJSASA-N 0.000 description 2
- 229960002390 flurbiprofen Drugs 0.000 description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 229960001002 nepafenac Drugs 0.000 description 2
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 229940054534 ophthalmic solution Drugs 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical group [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 229960002800 prednisolone acetate Drugs 0.000 description 2
- 229960004786 prednisolone phosphate Drugs 0.000 description 2
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 2
- 229960002117 triamcinolone acetonide Drugs 0.000 description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562189813P | 2015-07-08 | 2015-07-08 | |
| US62/189,813 | 2015-07-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018520045A Division JP6752276B2 (ja) | 2015-07-08 | 2016-07-07 | 眼炎症状態を処置する際に使用するための、インテグリンα４アンタゴニストを含む薬学的組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020121985A JP2020121985A (ja) | 2020-08-13 |
| JP2020121985A5 true JP2020121985A5 (enExample) | 2020-11-05 |
Family
ID=56373100
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018520045A Expired - Fee Related JP6752276B2 (ja) | 2015-07-08 | 2016-07-07 | 眼炎症状態を処置する際に使用するための、インテグリンα４アンタゴニストを含む薬学的組成物 |
| JP2020068158A Pending JP2020121985A (ja) | 2015-07-08 | 2020-04-06 | 眼炎症状態を処置する際に使用するための、インテグリンα４アンタゴニストを含む薬学的組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018520045A Expired - Fee Related JP6752276B2 (ja) | 2015-07-08 | 2016-07-07 | 眼炎症状態を処置する際に使用するための、インテグリンα４アンタゴニストを含む薬学的組成物 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10413535B2 (enExample) |
| EP (1) | EP3319639B1 (enExample) |
| JP (2) | JP6752276B2 (enExample) |
| KR (2) | KR102440162B1 (enExample) |
| CN (1) | CN107921136A (enExample) |
| AU (1) | AU2016290197B2 (enExample) |
| BR (1) | BR112018000112A2 (enExample) |
| CA (1) | CA2989522C (enExample) |
| CL (1) | CL2018000057A1 (enExample) |
| ES (1) | ES2835274T3 (enExample) |
| HK (1) | HK1247120A1 (enExample) |
| IL (2) | IL256770B (enExample) |
| MA (2) | MA42016A1 (enExample) |
| MX (1) | MX385229B (enExample) |
| MY (1) | MY187552A (enExample) |
| PL (1) | PL3319639T3 (enExample) |
| RU (1) | RU2018103940A (enExample) |
| TN (1) | TN2017000538A1 (enExample) |
| UA (1) | UA123728C2 (enExample) |
| WO (1) | WO2017006272A1 (enExample) |
| ZA (1) | ZA201708601B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018165218A1 (en) | 2017-03-09 | 2018-09-13 | Allysta Pharmaceuticals, Inc | Peptides for dry eye disease |
| WO2018212846A1 (en) * | 2017-05-19 | 2018-11-22 | Ocugen, Inc. | Ophthalmic compositions and methods of use |
| FI3873884T3 (fi) | 2018-10-30 | 2025-02-24 | Gilead Sciences Inc | 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa |
| JP7189368B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ， インコーポレイテッド | アルファ４ベータ７インテグリンの阻害のための化合物 |
| ES3013256T3 (en) | 2018-10-30 | 2025-04-11 | Gilead Sciences Inc | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| EP3873605B1 (en) | 2018-10-30 | 2024-10-23 | Gilead Sciences, Inc. | Compounds for inhibition of alpha4beta7 integrin |
| JP2022541851A (ja) * | 2019-07-26 | 2022-09-27 | アレグロ ファーマシューティカルズ エルエルシー | 眼の非滲出型黄斑変性および他の障害を治療するためのペプチド |
| WO2021030438A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| IL302175A (en) * | 2020-10-21 | 2023-06-01 | Azura Ophthalmics Ltd | Compounds and methods for the treatment of ocular disorders |
| KR102391198B1 (ko) * | 2021-08-27 | 2022-04-27 | 한림제약(주) | 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9828074D0 (en) * | 1998-12-18 | 1999-02-17 | Glaxo Group Ltd | Therapeutically useful compounds |
| GB0014892D0 (en) * | 2000-06-16 | 2000-08-09 | Glaxo Group Ltd | Novel pharmaceutical formulation |
| DK2444079T3 (en) | 2005-05-17 | 2017-01-30 | Sarcode Bioscience Inc | Compositions and Methods for the Treatment of Eye Diseases |
| JP2009514969A (ja) * | 2005-11-09 | 2009-04-09 | コンビナトアールエックス インコーポレーティッド | 医学的状態を治療するための方法、組成物、およびキット |
| US20130217657A1 (en) * | 2011-12-21 | 2013-08-22 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
-
2016
- 2016-07-07 JP JP2018520045A patent/JP6752276B2/ja not_active Expired - Fee Related
- 2016-07-07 RU RU2018103940A patent/RU2018103940A/ru unknown
- 2016-07-07 BR BR112018000112-0A patent/BR112018000112A2/pt not_active Application Discontinuation
- 2016-07-07 KR KR1020187003454A patent/KR102440162B1/ko active Active
- 2016-07-07 EP EP16736636.8A patent/EP3319639B1/en active Active
- 2016-07-07 UA UAA201800954A patent/UA123728C2/uk unknown
- 2016-07-07 MX MX2017017163A patent/MX385229B/es unknown
- 2016-07-07 CN CN201680040066.0A patent/CN107921136A/zh active Pending
- 2016-07-07 AU AU2016290197A patent/AU2016290197B2/en not_active Ceased
- 2016-07-07 KR KR1020227015200A patent/KR20220062688A/ko not_active Ceased
- 2016-07-07 US US15/742,867 patent/US10413535B2/en not_active Expired - Fee Related
- 2016-07-07 HK HK18106821.2A patent/HK1247120A1/zh unknown
- 2016-07-07 TN TNP/2017/000538A patent/TN2017000538A1/en unknown
- 2016-07-07 CA CA2989522A patent/CA2989522C/en active Active
- 2016-07-07 PL PL16736636T patent/PL3319639T3/pl unknown
- 2016-07-07 ES ES16736636T patent/ES2835274T3/es active Active
- 2016-07-07 MY MYPI2017001928A patent/MY187552A/en unknown
- 2016-07-07 WO PCT/IB2016/054073 patent/WO2017006272A1/en not_active Ceased
- 2016-07-07 MA MA42016A patent/MA42016A1/fr unknown
-
2017
- 2017-12-18 ZA ZA2017/08601A patent/ZA201708601B/en unknown
-
2018
- 2018-01-07 IL IL256770A patent/IL256770B/en active IP Right Grant
- 2018-01-08 CL CL2018000057A patent/CL2018000057A1/es unknown
- 2018-02-08 MA MA44935A patent/MA44935A1/fr unknown
-
2019
- 2019-09-12 US US16/569,465 patent/US10751334B2/en not_active Expired - Fee Related
-
2020
- 2020-04-06 JP JP2020068158A patent/JP2020121985A/ja active Pending
- 2020-07-13 US US16/927,825 patent/US20200405703A1/en not_active Abandoned
-
2021
- 2021-02-11 IL IL280827A patent/IL280827A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020121985A5 (enExample) | ||
| JP7475395B2 (ja) | 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法 | |
| JP7116490B2 (ja) | 眼の炎症性障害および疾患の組合せ処置 | |
| TWI376363B (en) | Pharmaceutical combination for treating demyelinating disease | |
| US20150133546A1 (en) | Sustained release delivery of one or more agents | |
| US12364685B2 (en) | Isoxazoline parasiticide formulations | |
| CA2899321C (en) | Fluorinated .alpha..nu.integrin antagonists | |
| US8299124B2 (en) | Aqueous intraocular penetration-promoting eye drop | |
| US20140171490A1 (en) | Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients | |
| CN111182893A (zh) | 包含f6h8的眼用组合物 | |
| JP6752276B2 (ja) | 眼炎症状態を処置する際に使用するための、インテグリンα４アンタゴニストを含む薬学的組成物 | |
| JP2022523548A5 (enExample) | ||
| JP2020063269A (ja) | 多発性硬化症を治療するための小児科の組成物 | |
| JP7571037B2 (ja) | 眼表面疼痛を治療する方法 | |
| BR112020008046A2 (pt) | composições e métodos de uso para tratamento de inflamação anormal em glândulas secretoras perioculares ou na superfície ocular | |
| AU2019263302A1 (en) | Liquid depot for non-invasive sustained delivery of agents to the eye | |
| US20110257186A1 (en) | Compositions and methods for treating visual disorders | |
| JP2020518562A (ja) | アルツハイマー病のイダロピルジン系組合せ療法 | |
| US20160095861A1 (en) | Ophthalmic ointments comprising valganciclovir hydrochloride for treating infective eye diseases |